Oliver Luxxe Assets LLC Trims Position in Halozyme Therapeutics, Inc. $HALO

Oliver Luxxe Assets LLC decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 34.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 33,014 shares of the biopharmaceutical company’s stock after selling 17,166 shares during the quarter. Oliver Luxxe Assets LLC’s holdings in Halozyme Therapeutics were worth $2,584,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Measured Wealth Private Client Group LLC increased its position in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the period. Harbour Investments Inc. boosted its holdings in shares of Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 372 shares during the last quarter. Clearstead Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 64.8% in the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 331 shares during the last quarter. Finally, Wexford Capital LP bought a new stake in Halozyme Therapeutics during the third quarter valued at approximately $70,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 1,923 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total value of $153,397.71. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $61,245,810.60. The trade was a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares in the company, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 72,477 shares of company stock valued at $5,102,643. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Up 20.2%

NASDAQ HALO opened at $103.12 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $103.30. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The stock has a market cap of $12.23 billion, a PE ratio of 30.78, a P/E/G ratio of 0.43 and a beta of 0.85. The stock’s 50 day moving average is $76.48 and its 200 day moving average is $71.47.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 232.11%. The business had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter in the previous year, the company earned $1.54 EPS. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

Analysts Set New Price Targets

Several research analysts have weighed in on HALO shares. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Friday. Finally, Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 price target for the company in a report on Friday. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.